Treats Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism. ANDA 214092, held by Sciegen Pharms. Carbidopa; Levodopa.
As of Nov 16, 2026, ANDA 214092 (Carbidopa And Levodopa), held by Sciegen Pharms, was first approved by FDA on May 7, 2021, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Carbidopa and levodopa tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 7, 2021 | Original application | Approved | None posted |
| Carbidopa And Levodopa10MG;100MG · tablet;oral | Carbidopa; Levodopa | Rx |
| Carbidopa And Levodopa25MG;100MG · tablet;oral | Carbidopa; Levodopa | Rx |
| Carbidopa And Levodopa25MG;250MG · tablet;oral | Carbidopa; Levodopa | Rx |
| Nov 9, 2026 | Supplement 11Labeling · Standard review | Approved | None posted |
| May 7, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters